5 Min Read
(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, link.reuters.com/mex49s; for the Morning News Call newsletter, link.reuters.com/nex49s)
U.S. stock indexes tumbled on Monday, the first trading day of the year, after weak Chinese economic data reignited fears of a global slowdown. The Dow Jones industrial average was down 2.17 percent at 17,046.35, the S&P 500 was down 2.01 percent at 2,002.85 and the Nasdaq Composite was down 2.48 percent at 4,883.191.
** VALEANT PHARMACEUTICALS INTERNATIONAL INC, $99.95, -1.67 pct
Billionaire investor William Ackman said on Thursday he sold about 5 million shares in the drug company in order to generate a tax loss as investors in his Pershing Square Capital Management face the biggest loss in the company's history.
** TESLA MOTORS INC, $223.49, -6.88 pct
The pioneering electric car maker said on Sunday that it delivered 17,400 vehicles in the fourth quarter of 2015, just above the low end of its forecast of 17,000-19,000.
Tesla delivered 208 of its new electric SUV, the Model X, in the quarter, below the expectations of some analysts. Robert W Baird analyst Ben Kallo, who had expected Tesla to deliver about 1,000 Model X cars, said deliveries were lower as "the Model X production ramp began later than we had expected" in the fourth quarter.
** NETFLIX INC, $106.53, -6.86 pct
Robert W. Baird & Co cut its rating on the video streaming service provider's shares to "neutral" from "outperform" and price target to $115 from $128. "Our quarterly U.S. subscriber survey suggests potentially weaker U.S. subscriber results for the second consecutive quarter, and while international may beat, we believe much of that is priced in," Baird analysts wrote in a note.
** BAXALTA INC, $39.99, +2.46 pct
The drugmaker said on Monday that it inked a deal with privately held Symphogen under which the companies would develop immuno-oncology drugs. The agreement holds a total potential value up to 1.4 billion euros ($1.6 billion) in option fees and milestones over the long term, in addition to royalties on worldwide sales, Baxalta said.
** UNILIFE CORP, $0.8356, +68.77 pct
The medical device maker entered into an exclusivity agreement with Amgen Inc, which paid a non-refundable $15 million deposit for an option to negotiate a potential transaction with Unilife until Jan. 31. Unilife, which makes injections and insulin patch pumps, said last year that it was reviewing strategic alternatives, including a sale, after getting interest from a possible buyer. A potential deal with Amgen could include a license to Unilife's existing proprietary devices, the purchase of up to 19.9 percent of its common stock, and manufacturing arrangements and rights between the companies.
** QUNAR CAYMAN ISLANDS LTD, $44.9, -14.87 pct
** CTRIP.COM INTERNATIONAL LTD, $44.44, -4.08 pct
** BAIDU INC, $181.311, -4.09 pct
** JD.COM INC, $30.04, -6.90 pct
** ALIBABA GROUP HOLDING LTD, $76.63, -5.71 pct
** YY INC, $61.025, -2.31 pct
** CHEETAH MOBILE INC, $15.11, -5.68 pct
** MOMO INC, $15.42, -3.75 pct
** KANDI TECHNOLOGIES GROUP INC, $10.24, -6.06 pct
** TARENA INTERNATIONAL INC, $10, -4.21 pct
** JINKOSOLAR HOLDING CO LTD, $25.89, -6.43 pct
U.S.-listed shares of Chinese companies fell after China's major stock indexes tanked on the first trading day of the year, triggering a "circuit-breaker" that suspended equities trade nation-wide for the first time. The decline was triggered by data that showed activity in the Chinese manufacturing sector contracted for a fifth straight month in December. The Shanghai Composite index closed down about 7 percent in its biggest daily decline since Aug. 25.
JinkoSolar shares fell also after it said on Friday that Arturo Herrero, its chief strategy officer of six years, had resigned, effective Monday.
** PANDORA MEDIA INC, $12.72, -5.15 pct
SunTrust Robinson Humphrey cut its rating on the music streaming company's shares to "neutral" from "buy" and price target to $15 from $18. "Despite the Copyright Royalty Board decision being behind us, we think the pursuit of new total addressable markets will increase near-term costs and risks, weighing against 2016 and 2017 profits," analysts wrote in a note. (Compiled by Abhirup Roy in Bengaluru; Editing by Kirti Pandey)